What other drugs will affect Sotagamma?
Tell your doctor about all your other medicines, especially:
other heart medications;
blood pressure medication; or
insulin or oral diabetes medicine.
This list is not complete. Other drugs may affect Sotagamma, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Why it's used
Sotagamma is a beta blocker. It’s used to treat:
- ventricular arrhythmia (Sotagamma)
- atrial fibrillation and atrial flutter (Sotagamma AF)
Find Lowest Prices on
BETAPACE (Sotagamma hydrochloride) Tablets
LIFE THREATENING PROARRHYTHMIA
To minimize the risk of drug-induced arrhythmia, initiate or reinitiate oral Sotagamma in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring.
Sotagamma can cause life threatening ventricular tachycardia associated with QT interval prolongation.
If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug.
Calculate creatinine clearance to determine appropriate dosing .
Brief Answer:Yes milk and dairy has to be taken after two hours
Detailed Answer:You are correct, Sotagamma has to be taken on empty stomach.Dairy products have calcium which reduces the absorption of most drugs. So Sotagamma is something which comes into this category.You can take hot tea/green tea without milk in it.
Let me know if you have any queries.
Betapace/Betapace AF contains Sotagamma hydrochloride, an antiarrhythmic drug with Class II (betaadrenoreceptor blocking) and Class III (cardiac action potential duration prolongation) properties. Betapace is supplied as a light-blue, capsule-shaped tablet for oral administration. Betapace AF is supplied as a white, capsule-shaped tablet for oral administration. Sotagamma hydrochloride is a white, crystalline solid with a molecular weight of 308.8. It is hydrophilic, soluble in water, propylene glycol and ethanol, but is only slightly soluble in chloroform. Chemically, Sotagamma hydrochloride is d,l-N-ethyl]phenyl]methane-sulfonamide monohydrochloride. The molecular formula is C12H20N2O3 S•HCl and is represented by the following structural formula:
What if I forget to take it?
If you miss a dose of Sotagamma, take it as soon as you remember, unless it is nearly time for your next dose. In this case, just leave out the missed dose and take your next dose as normal.
Never take 2 doses at the same time. Never take an extra dose to make up for a forgotten one.
If you often forget doses, it may help to set an alarm to remind you. You could also ask your pharmacist for advice on other ways to help you remember to take your medicine.
Sotagamma side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
fast or pounding heartbeats, fluttering in your chest;
sudden dizziness (like you might pass out);
slow heartbeats (especially if you feel light-headed);
swelling, rapid weight gain; or
feeling short of breath.
Common side effects may include:
feeling weak or tired.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Calcium channel blockers
Taking these drugs with Sotagamma can increase side effects, such as blood pressure that’s lower than normal. Examples of these drugs include:
Sotagamma can cover up the symptoms of low blood sugar, and it can cause high blood sugar. If you take Sotagamma with a diabetes medication that can cause a low blood sugar reaction, your dosage of the diabetes medication will need to be changed. Examples of these medications include:
QT Prolongation And Proarrhythmia
Betapace/Betapace AF can cause serious and potentially fatal ventricular arrhythmias such as sustained VT/VF, primarily Torsade de Pointes (TdP) type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. Factors such as reduced creatinine clearance, female sex, higher doses, reduced heart rate and history of sustained VT/VF or heart failure increase the risk of TdP. The risk of TdP can be reduced by adjustment of the Sotagamma dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval .
Correct hypokalemia or hypomagnesemia prior to initiating Betapace/Betapace AF, as these conditions can exaggerate the degree of QT prolongation, and increase the potential for Torsade de Pointes. Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs.
Proarrhythmic events must be anticipated not only on initiating therapy, but with every upward dose adjustment .
In general, do not use Sotagamma with other drugs known to cause QT prolongation .Sotagamma is a beta-adrenergic blocking drug that is used to treat abnormal heart rhythms. Sotagamma is a first generation beta blocker in a >
Sotagamma is effective in preventing the recurrence of a wide range of supraventricular tachycardias including AV nodal reentry, AV reentry, and atrial tachycardia, but its main clinical use lies in the treatment of AF and atrial flutter. In the AFFIRM trial, more than two-thirds of patients in the rhythm control arm were started on either amiodarone or Sotagamma. 70 While both drugs had a relatively low incidence of adverse effects severe enough to cause discontinuation at 1 year (11.1% vs. 12.3% ), therapy with class I antiarrhythmics had to be stopped more often (28.1% at 1 year) due to frequent adverse effects. However, amiodarone is clearly superior to Sotagamma and propafenone in maintaining sinus rhythm. 52 Although the impact of Sotagamma on primary prevention of SCD in patients recovering from MI has been disappointing, it does appear to decrease first defibrillation shock and death in some patients with ICDs. 71 Sotagamma also reduced the number of inappropriate ICD shocks, most likely due to its suppression of atrial arrhythmias, and unlike amiodarone, consistently decreases the defibrillation threshold in patients with ICDs. The lowering of the defibrillation threshold, along with the relative lack of noncardiac adverse effects with Sotagamma, makes it the first-line AAD for patients with ICDs.